Bergmann Rouven 4
4 · Medidata Solutions, Inc. · Filed Feb 7, 2019
Insider Transaction Report
Form 4
Bergmann Rouven
Chief Financial Officer
Transactions
- Sale
Common Stock
2019-02-05$75.00/sh−2,512$188,400→ 76,524 total - Sale
Common Stock
2019-02-06$75.00/sh−9,475$710,625→ 76,524 total - Exercise/Conversion
Stock Option (right to buy)
2019-02-05−525→ 17,118 totalExercise: $53.29Exp: 2025-05-13→ Common Stock (525 underlying) - Exercise/Conversion
Stock Option (right to buy)
2019-02-06−9,475→ 7,643 totalExercise: $53.29Exp: 2025-05-13→ Common Stock (9,475 underlying) - Exercise/Conversion
Common Stock
2019-02-05$53.29/sh+525$27,977→ 79,561 total - Sale
Common Stock
2019-02-05$75.00/sh−525$39,375→ 79,036 total - Exercise/Conversion
Common Stock
2019-02-06$53.29/sh+9,475$504,923→ 85,999 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 26, 2018.
- [F2]Included are 174 shares which were purchased pursuant to the terms of the Medidata Solutions, Inc. Employee Stock Purchase Plan on December 31, 2018.
- [F3]Such transaction was executed in multiple trades at prices ranging from $75.00 to $75.01. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]The options vested as to 25% of the shares on May 13, 2016 and 1/36th of the remaining options will become exercisable each month thereafter for the next 36 months.